CURE’s skin cancer page is an extensive resource of cancer information featuring the latest skin cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on skin cancer.
March 1st 2022
Better therapies are on the horizon for cancer that has spread to the brain, including a clinical trial that matches patients with treatments based on unique genetic changes in brain metastases.
February 22nd 2022
The goal of the phase 2 trial is to study the safety and efficacy of ASP-1929, a photoimmunotherapy with fluorescence imaging, in patients with head and neck or skin cancer.
February 11th 2022
I learned that a more prominent obstacle that we need to navigate is getting past the assumption that having a darker skin tone protects people from skin cancer.
January 28th 2022
Side effects from cancer treatment with immunotherapy, which may include vitiligo and certain rashes, may point to who will respond better to the treatment, although more research is needed to determine how much weight to put on these data.
January 26th 2022
Kimmtrak is the first-ever drug to be granted FDA approval for this patient population of HLA-A*02:01-positive metastatic or unresectable uveal melanoma.
January 25th 2022
Patients with metastatic cutaneous squamous cell carcinoma achieved promising response rates after treatment with cosibelimab. If approved, drug developers are hoping to offer cosibelimab as a more affordable immunotherapy option for this patient population.
January 14th 2022
From the deaths of singer Ronnie Spector and famed cancer researcher Beatrice Mintz to a patient who became his own biggest advocate after a stranger noticed a suspicious spot on his back, here’s what’s happening in the cancer landscape this week.
January 10th 2022
Patients with melanoma who consumed a high-fiber diet may have a better response to immunotherapy, although the benefit was not as great if the fiber was obtained via probiotic supplements.
January 10th 2022
The Food and Drug Administration is expected to decide on whether to approve certain cancer regimens within the first few months of the year. Here’s what patients with cancer should know.
January 7th 2022
Relatlimab plus Opdivo improved progression-free survival in patients with untreated, advanced melanoma, and tended to have fewer side effects than other regimens used in this patient population.
January 6th 2022
Certain allergy medications like Zyrtec and Claritin may be the key for more patients to tolerate immunotherapy for several cancer types.
January 5th 2022
The recent FDA approval of Keytruda, an immunotherapy monoclonal antibody drug, for children with melanoma is an exciting development, according to an expert. But there is potential for certain side effects that children and their family should consider before undergoing treatment.
December 27th 2021
As cancer incidence increases in young adults, understanding the genomic profiles of tumors in young adults may guide treatment options such as immunotherapy.
December 22nd 2021
The FDA’s recent greenlight of a new Keytruda indication gives a large group of patients with melanoma access to a treatment option that they didn’t previously have, says an expert from the UPMC Hillman Cancer Center.
December 20th 2021
While it may be tempting to slack off on sun protection when the rays aren’t beating down, it’s imperative to stay vigilant through the darker winter months.
December 15th 2021
Here’s a look back at CURE®’s top-performing melanoma content from the year 2021.
December 4th 2021
The FDA approved adjuvant Keytruda for patients ages 12 and older with stage 2b, 2c or 3 melanoma that has been completely resected.
November 29th 2021
Upfront immunotherapy was far superior to upfront BRAF/MEK inhibition in patients with metastatic BRAFV600-mutant melanoma, causing the phase 3 DREAMseq early to stop early.
November 26th 2021
Part B of the DIONE-01 study will look at whether IOA-244 increases anti-tumor responses in expansion groups of patients.
November 18th 2021
The combination of Opdivo and Yervoy may provide a survival benefit for asymptomatic patients with melanoma who have brain metastases, although more efforts are needed to include this patient population in trials.
November 4th 2021
Patients who experience side effects due to immune checkpoint inhibitors are 80% more likely to go to the emergency room and have 30% higher monthly medical costs, compared to patients who did not have side effects.
October 17th 2021
The first patient was enrolled and dosed in InflaRx’s phase 2 trial of vilobelimab for the treatment of cutaneous squamous cell carcinoma.
September 20th 2021
Exposure to certain high blood pressure drugs, specifically thiazide diuretics, may increase a person’s risk of developing skin cancer.
September 14th 2021
The overgrowth of fungi could cause the immune system to stop fighting cancer, according to a study.
September 1st 2021
Skin cancer rates have been increasing worldwide, and climate change factors – like depleting ozone layers – may be a factor.
August 20th 2021
From Dick Vitale’s early melanoma cancer detection to the authorization of COVID-19 vaccine booster shots for patients with cancer, here’s what’s happening in the cancer landscape this week.
August 17th 2021
The bacteria in a patient’s gut could be linked to side effects from combined checkpoint inhibitors in patients with melanoma.
August 15th 2021
Here are five options for overcoming stress and anxiety to promote your mental wellness and emotional resilience during your radiation therapy.
August 2nd 2021
Vitamin D is essential for strong bones and a healthy immune system. While a limited amount of the vitamin can be obtained from exposure to the sun’s ultraviolet (UV) radiation, the suggestion that the best way to obtain vitamin D is through sun exposure is both misleading and dangerous.